imino
sugar
antivir
therapi
flaviviru
filoviru
viral
hemorrhag
fever
b
r
c
endoplasm
reticulum
er
resid
aglucosidas
ii
sequenti
trim
three
termin
glucos
moieti
nlink
glycan
attach
nascent
glycoprotein
reaction
first
step
nlink
glycan
process
essenti
proper
fold
function
mani
glycoprotein
viral
envelop
glycoprotein
contain
nlink
glycan
inhibit
er
aglucosidas
deriv
dnj
castanospermin
cast
two
wellstudi
pharmacophor
aglucosidas
inhibitor
effici
disrupt
morphogenesi
broad
spectrum
envelop
virus
moreov
dnj
cast
deriv
demonstr
prevent
death
mice
infect
sever
distinct
flavivirus
filovirus
suppress
multipl
sever
speci
virus
infect
anim
nbutyl
deriv
dnj
nbdnj
obytanoyl
prodrug
cast
bucast
evalu
human
clinic
trial
antivir
activ
human
immunodefici
viru
hepat
c
viru
ongo
trial
treat
dengu
patient
bucast
articl
summar
current
statu
er
aglucosidasetarget
antivir
therapi
propos
strategi
develop
efficaci
specif
er
aglucosidas
inhibitor
broadspectrum
drug
resistancerefractori
antivir
therapeut
host
functiontarget
broadspectrum
antivir
agent
reli
timeconsum
etiolog
diagnosi
therefor
particularli
promis
manag
viral
hemorrhag
fever
respiratori
tract
viral
infect
medic
condit
caus
mani
differ
envelop
rna
virus
short
window
medic
intervent
rna
polymeras
integras
proteas
neuraminidas
antivir
activ
directact
antivir
agent
usual
virusspecif
numer
exampl
treatment
failur
due
emerg
drugresist
virus
contrast
target
host
function
essenti
viral
replic
consid
potenti
broadspectrum
resistancerefractori
therapeut
approach
accordingli
mani
host
cellular
protein
involv
nucleosid
metabol
rna
cap
protein
fold
glycan
process
empir
explor
broadspectrum
antivir
target
de
clercq
geller
et
al
recent
advent
genomewid
technolog
allow
systemat
identif
valid
potenti
host
cellular
target
antivir
drug
develop
de
chassey
et
al
honggel
michevaviteva
meliopoulo
et
al
watanab
et
al
although
mani
inhibitor
host
function
demonstr
inhibit
specif
viru
broad
spectrum
virus
cultur
cell
vivo
antivir
efficaci
far
demonstr
inhibitor
host
enzym
includ
monophosph
dehydrogenas
impdh
furuta
et
al
sadenosyllhomocystein
sah
hydrolas
bray
et
al
bray
et
al
cyclophilin
inou
et
al
endoplasm
reticulum
er
aglucosidas
nobl
et
al
er
aglucosidas
inhibitor
particular
dnj
castanopermin
cast
deriv
demonstr
last
three
decad
mani
independ
research
group
inhibit
morphogenesi
mani
envelop
virus
review
dwek
et
al
sever
dnj
cast
deriv
demonstr
reduc
viremia
dengu
viru
denv
andor
protect
mice
lethal
dose
denv
chang
et
al
b
miller
et
al
perri
et
al
rathor
et
al
schul
et
al
watanab
et
al
whitbi
et
al
japanes
enceph
viru
jev
wu
et
al
ebola
viru
ebov
marburg
viru
marv
challeng
mice
reduct
viremia
dnj
deriv
nnonyldnj
nndnj
also
shown
vivo
woodchuck
chronic
infect
woodchuck
hepat
viru
whv
model
viru
human
hepat
b
viru
hbv
block
et
al
furthermor
human
clinic
trial
nbdnj
bucast
perform
test
antivir
efficaci
human
immunodefici
viru
hiv
hepat
c
viru
hcv
respect
case
modest
reduct
viru
titer
serum
treat
patient
observ
durantel
fischl
et
al
studi
thu
far
valid
host
cellular
er
aglucosidas
viabl
drug
target
treatment
broad
spectrum
envelop
virus
broadspectrum
antivir
agent
would
particularli
promis
manag
viral
hemorrhag
fever
respiratori
tract
viral
infect
medic
condit
caus
mani
differ
virus
short
treatment
window
medic
intervent
hussel
et
al
jartti
et
al
paessler
walker
develop
drug
broadspectrum
antivir
activ
acut
infect
obvious
hold
clear
clinic
advantag
comparison
virusspecif
antivir
agent
reli
timeconsum
etiolog
diagnosi
er
aglucosidas
ii
key
enzym
nlink
glycan
process
nascent
glycoprotein
protein
synthes
er
glycoprotein
nlink
glycosyl
common
type
glycosyl
process
occur
er
lumen
eukaryot
initi
addit
preform
oligosaccharid
precursor
glc
man
glcnac
asparagin
motif
nascent
polypeptid
oligosaccharyltransferas
nlink
oligosaccharid
moieti
serv
highli
divers
function
essenti
fold
sort
secret
function
glycoprotein
heleniu
aebi
illustr
fig
initi
step
nlink
oligosaccharid
process
glycoprotein
er
involv
sequenti
trim
three
glucos
residu
oligosaccharid
two
er
glycosid
cleav
enzym
aglucosidas
ii
aglucosidas
remov
outer
glucos
residu
aglucosidas
ii
remov
two
inner
ing
function
mani
glycoprotein
allow
interact
er
chaperon
calnexin
calreticulin
hebert
et
al
er
contain
uniqu
calnexindepend
fold
qualiti
control
machineri
calnexincalreticulin
act
chaperon
bind
protein
monoglucosid
glycan
side
chain
incomplet
fold
protein
reglucosyl
udpglucosyltransferas
serv
sensor
correct
protein
fold
properli
fold
protein
eventu
releas
reand
deglucosyl
cycl
move
golgi
complex
process
hammond
et
al
abrog
normal
glycoprotein
traffick
process
inhibit
er
aglucosidas
ii
result
termin
glucos
retent
nlink
glycan
subsequ
gener
misfold
glycoprotein
may
retain
er
ultim
direct
undergo
erassoci
degrad
erad
simsek
et
al
misfold
glycoprotein
manag
escap
er
qualiti
control
end
express
cell
surfac
presenc
glucosidas
inhibit
may
present
compromis
function
burk
et
al
mclaughlin
vandenbroeck
envelop
protein
mani
differ
virus
glycoprotein
contain
nlink
glycan
mammalian
virus
encod
carbohydratemodifi
enzym
anticip
glycan
process
proper
fold
viral
glycoprotein
requir
host
cellular
er
aglucosidas
moreov
due
highli
dynam
natur
viral
replic
conceiv
inhibit
er
aglucosidas
might
preferenti
disturb
matur
function
viral
envelop
glycoprotein
may
consequenti
reduc
virion
particl
assembl
secret
andor
infect
inde
essenti
role
cellular
er
aglucosidas
ii
denv
life
cycl
demonstr
genomewid
sirna
knockdown
studi
session
et
al
addit
suppress
er
aglucosidas
andor
ii
express
rna
interfer
technolog
effici
reduc
yield
envelop
rna
virus
denv
hcv
qu
et
al
yu
et
al
inhibit
er
aglucosidas
compromis
replic
broad
spectrum
envelop
virus
via
distinct
mechan
mani
natur
product
contain
inhibitor
variou
type
glucosidas
extens
explor
applic
medicin
carbohydratemedi
diseas
cancer
diabet
infect
lysosom
storag
diseas
kajimoto
node
moorthi
et
al
tundi
et
al
among
natur
product
dnj
cast
well
document
broadspectrum
antivir
activ
inhibit
er
aglucosidas
ii
dnj
cast
gener
refer
imino
sugar
shown
fig
dnj
polyhydroxyl
secondari
amin
molecul
resembl
monosaccharid
glucos
ring
oxygen
replac
nitrogen
cast
indolizidin
imino
sugar
ethylen
link
endocycl
nitrogen
creat
fuse
system
imino
sugar
similar
structur
glucos
substrat
er
aglucosidas
competit
inhibit
er
aglucosidas
ii
transitionst
substrat
analogu
hempel
et
al
dnj
cast
well
deriv
demonstr
inhibit
replic
envelop
virus
least
differ
famili
vitro
nobl
et
al
silber
et
al
although
virus
distinct
genom
structur
replic
strategi
envelop
glycosyl
viral
protein
therefor
share
similar
morphogenesi
pathway
depend
host
glycoprotein
process
machineri
er
howev
seem
viral
glycoprotein
equal
depend
mechan
achiev
function
conform
exampl
wnv
rel
less
sensit
imino
sugar
aglucosidas
inhibitor
flavivirus
denv
chang
et
al
whitbi
et
al
addit
certain
strain
vsv
orsay
influenza
viru
also
report
insensit
er
aglucosidas
inhibitor
datema
et
al
schlesing
et
al
concern
antivir
mechan
imino
sugar
one
anticip
biochem
consequ
suppress
er
aglucosidas
product
viral
glycoprotein
hyperglycosyl
glycan
side
chain
demonstr
mobil
shift
intracellular
viral
glycoprotein
electrophoresi
chang
et
al
hammond
et
al
taylor
et
al
directli
confirm
analyz
glycan
structur
attach
specif
viral
glycoprotein
ritchi
et
al
consequ
incomplet
glucos
trim
nlink
oligosaccharid
product
fold
pathway
viral
glycoprotein
affect
usual
result
reduc
effici
virion
assembl
secret
degrad
viral
glycoprotein
bear
unprocess
nlink
oligosaccharid
fact
well
document
imino
sugar
dosedepend
induc
mobil
shift
well
degrad
envelop
glycoprotein
virus
sever
famili
chang
et
al
fukushi
et
al
qu
et
al
occasion
incomplet
glucos
trim
also
affect
virion
secret
prevent
process
traffick
viral
glycoprotein
instanc
inhibit
er
aglucosidas
delay
format
reduc
stabil
denv
prme
heterodim
courageot
et
al
block
proteolyt
cleavag
sindbi
viru
precursor
envelop
glycoprotein
datema
et
al
howev
inhibit
glycan
process
imino
sugar
alway
result
degrad
andor
disrupt
intracellular
traffick
certain
viral
glycoprotein
instanc
demonstr
although
oligosaccharid
vsv
g
protein
influenza
viru
hemagglutinin
greatli
alter
presenc
glucosidas
inhibitor
surfac
express
inhibit
burk
et
al
studi
show
antivir
effect
chang
nlink
glycan
structur
becom
obviou
low
concentr
degrad
viral
glycoprotein
usual
occur
cell
treat
much
higher
concentr
glucosidas
inhibitor
chang
et
al
du
et
al
fukushi
et
al
yu
et
al
addit
suppress
virion
assembl
secret
antivir
activ
glucosidas
inhibitor
exampl
might
explain
mechan
inde
inhibit
nlink
glycan
process
viral
glycoprotein
could
also
result
secret
virion
alter
molecular
composit
bind
properti
andor
function
tabl
broadspectrum
antivir
activ
imino
sugar
multipl
famili
envelop
virus
vitro
virus
sensit
aglucosidas
fischer
et
al
fischer
et
al
taylor
et
al
taylor
et
al
datema
et
al
saito
yamaguchi
prevent
infect
suscept
cell
one
extrem
case
cmv
infect
cell
continu
shed
virion
extracellular
medium
presenc
cast
determin
electron
microscopi
antivir
effect
mainli
due
reduct
infect
result
alter
compon
virion
envelop
taylor
et
al
anoth
exampl
imino
sugar
inhibit
hiv
infect
bind
step
prevent
conform
chang
glycoprotein
fischer
et
al
fischer
et
al
nevertheless
envelop
virus
like
reduct
virion
secret
infect
respons
overal
antivir
effect
chapel
et
al
fischer
et
al
lazar
et
al
addit
wellstudi
mechan
also
possibl
inhibit
er
aglucosidas
compromis
express
andor
function
viral
receptor
sinc
mani
also
glycoprotein
nlink
glycan
studi
report
hiv
infect
pretreat
hivpermiss
cell
bucast
substanti
reduc
capac
bind
cell
chronic
infect
test
hypothesi
recent
test
effect
sever
dnjderiv
infect
retrovirus
pseudotyp
envelop
protein
eight
differ
famili
virus
demonstr
compound
effici
inhibit
sever
acut
respiratori
syndrom
coronaviru
sarscov
human
coronaviru
spike
proteinmedi
entri
zhao
guo
unpublish
observ
taken
togeth
studi
thu
far
illustr
imino
sugar
inhibit
broad
spectrum
envelop
virus
disrupt
virion
assemblysecret
reduc
infect
progeni
virion
alter
virion
andor
cellular
receptor
compon
absenc
effect
cell
viabil
distinct
antivir
mechan
consist
ontarget
inhibit
er
aglucosidas
subsequ
disrupt
viral
host
cellular
glycoprotein
process
although
demonstr
broadli
activ
antivir
agent
antivir
activ
dnj
cast
two
lead
aglucosidas
inhibitor
initi
discov
plant
horn
et
al
less
optim
therefor
limit
use
exampl
usual
requir
millimolar
concentr
dnj
inhibit
virus
thu
extens
lead
optim
effort
made
obtain
dnj
deriv
improv
antivir
efficaci
review
moorthi
et
al
nash
et
al
sayc
et
al
howev
due
lack
structur
inform
human
er
aglucosidas
lead
optim
effort
thu
far
empir
mention
dnj
substrat
glucos
analogu
competit
inhibit
er
aglucosidas
ii
far
limit
attempt
alter
dnj
core
structur
either
yield
deriv
significantli
improv
antivir
activ
result
loss
enzymat
inhibitori
activ
horn
et
al
zitzmann
et
al
except
fivememb
iminocyclitol
glucosidas
inhibitor
demonstr
antivir
activ
asano
et
al
chapman
et
al
liang
et
al
contrast
nitrogen
atom
dnj
ring
structur
provid
uniqu
opportun
gener
class
deriv
dnj
head
group
variou
nlink
alkyl
side
chain
last
two
decad
dnj
deriv
distinct
length
composit
nlink
side
chain
synthes
sever
strategi
use
diversifi
sidechain
structur
includ
heteroatom
substitut
addit
termin
ring
structur
conform
restrict
extens
comparison
antivir
activ
obtain
dnj
deriv
submicromolar
antivir
activ
sever
differ
virus
chang
et
al
interestingli
appear
compound
potent
antivir
activ
usual
similar
length
side
chain
approxim
linear
alkyl
side
chain
linear
chain
link
termin
ring
structur
howe
et
al
yu
et
al
fig
possibl
hydrophob
side
chain
anchor
dnj
deriv
er
membran
present
dnj
head
toward
activ
center
aglucosidas
kajimoto
node
moorthi
et
al
henc
conceiv
proper
length
side
chain
critic
optim
inhibit
er
aglucosidas
also
integr
er
membran
protein
addit
also
notic
among
dnj
deriv
improv
antivir
activ
alway
correl
increas
potenc
inhibit
er
aglucosidas
cellfre
biochem
assay
chang
et
al
howe
et
al
chang
et
al
unpublish
observ
one
explan
phenomenon
chang
nlink
side
chain
may
alway
enhanc
potenc
inhibit
target
enzym
may
also
improv
cell
penetr
andor
distribut
er
membran
fleet
et
al
karpa
et
al
moorthi
et
al
yu
et
al
thu
enhanc
antivir
activ
recent
crystal
structur
yeast
er
aglucosidas
determin
togeth
model
bind
substrat
inhibitor
barker
rose
yeast
human
aglucosidas
share
high
ident
catalyt
activ
domain
similar
substrat
specif
ph
optimum
inhibitor
sensit
schweden
et
al
therefor
structur
inform
obtain
yeast
er
aglucosidas
may
thu
facilit
ration
design
potent
specif
imino
sugaror
new
pharmacophor
er
aglucosidas
inhibitor
moorthi
et
al
sar
work
focus
dnj
deriv
limit
modif
perform
cast
partli
due
complic
chemic
natur
pharmacophor
progress
understand
structur
featur
er
aglucosidas
also
possibl
ration
design
modif
cast
made
futur
lead
optim
effort
success
identifi
imino
sugar
deriv
superior
antivir
activ
also
favor
pharmacokinet
toxicolog
properti
vivo
antivir
efficaci
studi
fig
list
dnj
cast
deriv
test
anim
model
viru
infect
sever
pioneer
work
prove
concept
imino
sugar
deriv
efficaci
reduc
viremia
whv
chronic
infect
woodchuck
block
et
al
tissu
viru
load
murin
zosteriform
model
infect
inhibit
rauscher
murin
leukemia
viru
infect
mice
ruprechat
et
al
develop
imino
sugar
treatment
chronic
human
viral
diseas
chronic
hepat
b
hepat
c
aid
discourag
long
term
imino
sugar
treatment
result
mild
reduct
viremia
small
proport
treat
individu
brought
limit
clinic
benefit
clinic
trial
treat
hiv
hcvinfect
patient
durantel
fischl
et
al
although
failur
could
due
use
earli
gener
imino
sugar
deriv
low
vitro
antivir
potenc
anoth
consider
differ
treatment
goal
chronic
acut
infect
contrast
requir
erad
signific
reduct
viremia
chronic
viral
infect
mani
acut
viral
infect
viral
hemorrhag
fever
caus
virus
four
differ
famili
reduct
viremia
log
earli
phase
infect
could
lifesav
nobl
et
al
vaughn
et
al
addit
mention
previou
section
antivir
broadli
activ
four
famili
hemorrhag
fever
virus
clear
clinic
advantag
directact
antivir
drug
select
inhibit
specif
virus
appear
imino
sugar
perfectli
meet
criteria
surprisingli
summar
tabl
variou
imino
sugar
deriv
thu
far
test
sever
mous
model
hemorrhag
fever
viru
infect
includ
denv
ebov
marv
demonstr
signific
antivir
potenc
dengu
hemorrhag
fever
common
viral
hemorrhag
fever
threaten
onethird
world
popul
without
approv
antivir
therapi
shown
tabl
sever
imino
sugar
deriv
demonstr
multipl
research
group
efficaci
reduc
denv
viremia
prevent
lethal
mous
infect
model
particularli
signific
protect
lethal
dengu
viru
infect
could
observ
dnj
deriv
bucast
treatment
initi
day
infect
suggest
therapeut
valu
post
exposur
treatment
furthermor
recent
demonstr
imino
sugar
could
effici
protect
mice
lethal
dose
challeng
ebov
marv
two
dread
hemorrhag
fever
virus
studi
becom
clear
major
case
order
achiev
close
protect
lethal
infect
andor
signific
reduct
viremia
greater
mgkg
twicedaili
dose
imino
sugar
requir
low
mgkg
three
time
day
also
result
signific
protect
mgkg
daili
provid
benefit
result
consist
rel
short
halflif
imino
sugar
compound
chang
et
al
perri
et
al
watanab
et
al
effort
confirm
therapeut
mechan
imino
sugar
vivo
demonstr
antivir
efficaci
imino
sugar
correl
inhibitori
effect
er
aglucosidas
suggest
analyz
proteinfre
oligosaccharid
fo
serum
treat
anim
block
et
al
chang
et
al
chang
et
al
specif
result
er
aglucosidas
inhibit
hyperglucosyl
fo
termin
glucos
retent
glc
man
glcnac
glc
man
glcnac
observ
accumul
treat
anim
thu
support
notion
antivir
effect
like
propos
antivir
mechan
vivo
howev
imino
sugar
deriv
effici
protect
lethal
denv
infect
compound
reduc
peak
viremia
infect
mice
less
except
one
studi
greater
reduct
viremia
post
peak
time
point
least
reduct
tissu
viru
load
record
chang
et
al
perri
et
al
schul
et
al
watanab
et
al
observ
rais
possibl
imino
sugar
deriv
prevent
denvinduc
death
mice
inhibit
viru
propag
also
suppress
viral
pathogenesi
later
possibl
particularli
consist
critic
role
interact
denv
envelop
glycan
host
cellular
patternrecognit
receptor
ctype
lectin
denv
pathogenesi
mice
chen
et
al
gener
acknowledg
massiv
product
inflammatori
cytokin
secondari
macrophag
dendrit
cell
infect
hemorrhag
fever
virus
play
import
role
pathogenesi
viral
hemorrhag
fever
geisbert
jahrl
howev
molecular
mechan
virusinduc
cytokin
storm
cytokin
mediat
blood
vessel
leakag
tissu
damag
remain
elus
hemorrhag
fever
virus
case
denv
infect
demonstr
mous
embryon
fibroblast
deriv
rigiand
mice
denv
infect
sequenti
recogn
two
cytoplasm
rna
helicas
receptor
rigiand
sens
denv
infect
two
receptor
result
activ
type
ifn
proinflammatori
cytokin
express
via
adaptor
protein
mav
cardif
visa
depend
activ
nfkb
signal
pathway
loo
et
al
howev
denv
infect
macrophag
induc
strong
type
ifn
proinflammatori
cytokin
respons
simultan
activ
plasma
membran
ctype
lectin
receptor
recogn
oligosaccharid
viral
envelop
glycoprotein
endosom
presum
recogn
viral
genom
rna
chen
et
al
illustr
fig
engag
two
patternrecognit
receptor
viral
compon
activ
signal
cascad
recruit
distinct
adaptor
molecul
induc
proinflammatori
cytokin
type
interferon
macrophag
critic
role
proinflammatori
cytokin
denv
pathogenesi
elegantli
demonstr
blockad
interact
monoclon
antibodi
inhibit
product
proinflammatori
cytokin
also
allevi
subcutan
vitalorgan
hemorrhag
symptom
reduc
mortal
infect
mice
chen
et
al
henc
entir
possibl
reduc
denv
secret
andor
alter
glycan
structur
viral
envelop
glycoprotein
imino
sugar
deriv
might
inhibit
inflammatori
cytokin
product
consequenti
allevi
viral
pathogenesi
inde
sever
studi
demonstr
signific
reduct
inflammatori
cytokin
level
upon
treatment
denv
infect
anim
imino
sugar
perri
et
al
schul
et
al
therefor
potenti
antiinflammatori
activ
imino
sugar
er
aglucosidas
inhibitor
investig
denv
hemorrhag
fever
viru
infect
imino
sugar
deriv
miglitol
glyset
miglustat
zavesca
nbdnj
approv
regulatori
author
treatment
noninsulindepend
diabet
lysosom
storag
diseas
gaucher
diseas
respect
antivir
applic
bucast
celgosivir
evalu
clinic
trial
hiv
hcv
infect
case
modest
antivir
effect
report
trial
hiv
discontinu
bucast
evalu
phase
iib
trial
demonstr
synergist
effect
combin
pegyl
plu
ribavirin
patient
hcv
infect
durantel
howev
unclear
develop
path
agent
current
posit
given
avail
much
potent
drug
condit
recent
random
doubleblind
placebocontrol
phase
ib
clinic
studi
evalu
activ
pharmacokinet
safeti
toler
bucast
adult
confirm
dengu
fever
initi
singapor
base
efficaci
devn
infect
mous
model
rathor
et
al
schul
et
al
watanab
et
al
among
dnj
deriv
nbdnj
zavesca
miglustat
evalu
phase
ii
trial
hiv
infect
limit
efficaci
mainli
due
low
potenc
difficulti
achiev
steadyst
therapeut
concentr
vivo
fischl
et
al
none
new
gener
dnj
deriv
demonstr
significantli
improv
antivir
potenc
reach
point
clinic
trial
consid
antivir
potenc
imino
sugar
treatment
goal
differ
viral
infect
like
therapeut
applic
dnj
deriv
acut
viral
infect
particularli
viral
hemorrhag
fever
respiratori
tract
viral
infect
promis
antivir
efficaci
denv
filovirus
mice
warrant
develop
broadspectrum
antivir
agent
hemorrhag
fever
virus
addit
potent
protect
effect
dnj
deriv
fig
http
potent
antivir
activ
uniqu
antivir
mechan
dnj
deriv
sarscov
fukushi
et
al
also
make
imino
sugar
deriv
potenti
broadspectrum
antivir
agent
respiratori
envelop
rna
viru
infect
addit
therapeut
efficaci
import
safeti
inform
obtain
clinic
trial
gener
bucast
well
toler
week
treatment
mgday
dose
without
seriou
advers
event
mild
moder
revers
gastrointestin
symptom
includ
flatul
diarrhea
report
half
treat
individu
could
control
antidiarrhea
agent
lowsucrosestarch
highglucos
diet
durantel
roth
et
al
similar
degre
gastrointestin
side
effect
also
observ
nbdnj
trial
tierney
et
al
dnjand
castderiv
two
current
avail
pharmacophor
er
aglucosidas
inhibitor
glucos
mimet
inhibit
er
aglucosidas
also
host
glucosidas
use
glucos
substrat
includ
intestin
disaccharidas
maltas
lactas
sucros
enzym
hydrolyz
ingest
carbohydr
disaccharid
monosaccharid
reuser
wisselaar
surprisingli
one
common
sideeffect
antivir
compound
intestin
stress
osmot
diarrhea
intestin
disaccharidas
local
brush
border
small
intestin
activ
site
face
lumen
side
effect
larg
associ
oral
administr
imino
sugar
therefor
could
avoid
parenter
rout
administr
altern
oral
avail
prodrug
imino
sugar
explor
exampl
bucast
oral
prodrug
cast
rapidli
convert
cast
bodi
anoth
approach
ester
prodrug
dnj
hydrolyz
circul
intracellular
compart
ubiquit
esteras
thu
avoid
inhibit
gut
glucosidas
lieder
borchardt
perbutyryl
ester
prodrug
nbdnj
demonstr
improv
safeti
profil
parent
compound
howev
bioavail
compromis
speci
anim
due
less
effici
convers
rate
cook
et
al
addit
prodrug
approach
could
increas
exposur
drug
plasma
achiev
efficaci
dose
improv
metabol
stabil
drug
increas
halflif
futur
approach
explor
optim
safeti
profil
bioconvers
imino
sugar
prodrug
principl
antivir
efficaci
safeti
profil
imino
sugar
improv
computerassist
design
novel
imino
sugar
deriv
potent
select
inhibit
human
er
aglucosidas
achiev
goal
facilit
recent
determin
crystal
structur
yeast
er
aglucosidas
barker
rose
addit
ertarget
deliveri
design
imino
sugar
deriv
increas
hydrophob
er
distribut
also
viabl
approach
improv
antivir
efficaci
imino
sugar
inde
demonstr
target
deliveri
imino
sugar
liposom
er
membran
immens
improv
antivir
activ
cultur
cell
vivo
mice
denv
miller
et
al
pollock
et
al
moreov
order
improv
er
aglucosidas
target
antivir
therapi
imino
sugar
chemic
space
explor
select
inhibitor
er
aglucosidas
may
substrat
analogu
target
catalyt
center
may
similar
er
glucosidas
intestin
glucosidas
compound
target
alloster
site
uniqu
er
aglucosidas
fact
approach
explor
other
identif
gut
maltasespecif
inhibitor
treatment
diabet
hakamata
et
al
develop
conveni
fluoresc
substratebas
vitro
enzymat
assay
er
aglucosidas
first
step
toward
discoveri
novel
alloster
inhibitor
may
ultim
improv
er
aglucosidasetarget
antivir
therapi
hakamata
et
al
summari
cellular
er
aglucosidas
among
host
enzym
demonstr
valid
target
broad
spectrum
envelop
virus
particularli
caus
hemorrhag
fever
howev
current
avail
imino
sugar
deriv
still
highli
efficaci
produc
modest
reduct
viremia
requir
high
frequent
dose
mild
side
effect
due
nonselect
inhibit
gut
glucosidas
futur
combin
effort
ration
design
chemic
modif
ertarget
drug
deliveri
prodrug
design
improv
efficaci
safeti
profil
imino
sugar
ultim
pave
way
clinic
addit
discoveri
novel
alloster
er
aglucosidas
inhibitor
new
direct
toward
improv
er
aglucosidasetarget
antivir
therapi
